Trial · NCT03733990
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
NCT03733990, Phase 1, Phase 2, Completed, Faron Pharmaceuticals Ltd; results first posted 2025-04-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS). Trials, record NCT03733990. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03733990
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
- NCT number
- NCT03733990
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 216 participants, actual
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Conditions
- Cancer
- Interventions
- FP-1305 (bexmarilimab)
- First posted
- 2018-11-07
- Last updated
- 2025-04-02
- Other registries' IDs
- eudract:2018-002732-24
- Results first posted
- 2025-04-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Limiting Toxicities (DLT) in the Trial Subjects. | Up to one year | Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects. |
| Primary | Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | approximately 4 years and 9 months | Number of adverse events and serious adverse events. Adverse events are collected, graded and reported according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. |
| Primary | The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. | approximately 4 years and 9 months | The objective response rate (ORR) to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1. Results from each tumour type, dose level and dosing frequency are reported separately. |
| Primary | The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. | approximately 4 years and 9 months | The disease control rate (DCR) response to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1 are presented by cycles and by doing so there is no difference in the definition of DCR and Clinical Benefit Rate (CBR) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Dose Limiting Toxicities (DLT) in the Trial Subjects. | Up to one year | DLT | NUMBER | |
| PRIMARY | Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | approximately 4 years and 9 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. | approximately 4 years and 9 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1. | approximately 4 years and 9 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 0.3 mg/kg | 0 | DLT | ||
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 1 mg/kg | 0 | DLT | ||
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 3 mg/kg | 0 | DLT | ||
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 10 mg/kg | 0 | DLT | ||
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 0.1 mg/kg | 0 | DLT | ||
| Dose Limiting Toxicities (DLT) in the Trial Subjects. | FP-1305 (Bexmarilimab) 30 mg/kg | 0 | DLT | ||
| Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | FP-1305 (Bexmarilimab) 0.3 mg/kg | 13 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | FP-1305 (Bexmarilimab) 1 mg/kg | 122 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | FP-1305 (Bexmarilimab) 3 mg/kg | 38 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) | FP-1305 (Bexmarilimab) 10 mg/kg | 17 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 0.3 mg/kg | 13 | |
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 1 mg/kg | 130 | |
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 3 mg/kg | 41 | |
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 10 mg/kg | 18 | |
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 0.1 mg/kg | 5 | |
| Overall Study | STARTED | FP-1305 (Bexmarilimab) 30 mg/kg | 9 | |
| Overall Study | COMPLETED | FP-1305 (Bexmarilimab) 0.3 mg/kg | 13 | |
| Overall Study | COMPLETED | FP-1305 (Bexmarilimab) 1 mg/kg | 130 | |
| Overall Study | COMPLETED | FP-1305 (Bexmarilimab) 3 mg/kg | 41 | |
| Overall Study | COMPLETED | FP-1305 (Bexmarilimab) 10 mg/kg | 18 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events558
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 0.3 mg/kg | 2 | 13 | 3 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 1 mg/kg | 32 | 130 | 52 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 3 mg/kg | 11 | 41 | 15 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 10 mg/kg | 6 | 18 | 11 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 0.1 mg/kg | 1 | 5 | 1 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | FP-1305 (Bexmarilimab) 30 mg/kg | 2 | 9 | 2 |
| other | Cardiac disorders | Cardiac disorders | FP-1305 (Bexmarilimab) 0.3 mg/kg | 0 | 13 | |
| other | Cardiac disorders | Cardiac disorders | FP-1305 (Bexmarilimab) 1 mg/kg | 3 | 130 | 7 |
| other | Cardiac disorders | Cardiac disorders | FP-1305 (Bexmarilimab) 3 mg/kg | 1 | 41 | 1 |
| other | Cardiac disorders | Cardiac disorders | FP-1305 (Bexmarilimab) 10 mg/kg | 1 | 18 | 1 |
1 to 10 of 558Source ClinicalTrials.gov
See all 558 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 0.3 mg/kg | 0 | 13 |
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 1 mg/kg | 12 | 130 |
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 3 mg/kg | 3 | 41 |
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 10 mg/kg | 3 | 18 |
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 0.1 mg/kg | 0 | 5 |
| Total, all-cause mortality | FP-1305 (Bexmarilimab) 30 mg/kg | 0 | 9 |
| Total, other adverse events | FP-1305 (Bexmarilimab) 0.3 mg/kg | 13 | 13 |
| Total, other adverse events | FP-1305 (Bexmarilimab) 1 mg/kg | 122 | 130 |
| Total, other adverse events | FP-1305 (Bexmarilimab) 3 mg/kg | 38 | 41 |
| Total, other adverse events | FP-1305 (Bexmarilimab) 10 mg/kg | 17 | 18 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03733990
GET https://conductscience.org/api/trials/v1/NCT03733990/results?page=2